Pharmacist Registrant 39

Pharmacist Registrant 39 has satisfied the terms of a Consent Agreement reached with the Inquiry Committee on December 19, 2018. The pharmacist registrant’s name has been withheld pursuant to s. 39.3(4) of the Health Professions Act.

December 19, 2018
(February 18, 2022 - Limits and Conditions Removed)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on September 24, 2018. Pursuant to section 32.2(4)(b)(i) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings. The undertakings include, but are not limited to:

  1. The Registrant will comply with any and all recommendations and treatment prescribed or directed by current physicians;
     
  2. The Registrant undertakes to adhere to routine medical monitoring program with the institution currently involved in the case and remain on the monitoring program for a minimum of 36 consecutive months of uninterrupted and verified abstinence and compliance from the day the Registrant returns to active employment as a pharmacist;
     
  3. In the event of any interruption to the agreed monitoring schedule set out by the medical monitoring program, the Registrant will advise the College of the interruption as soon as possible and provide an explanation for the interruption;
     
  4. The Registrant will not have access whatsoever, on or off-duty, to the narcotic safe in any pharmacy for at least one year from the date the Registrant returns to work;
     
  5. The Registrant will not be involved in any way with ordering mood altering drugs (narcotics, opiates, opioids, benzodiazepines, and atypical sedatives such as zopiclone, zaleplon, and zolpidem and prescription psychostimulants such as dextroamphetamine, methylphenidate and modafinil), except for signing off on the necessary paperwork in the presence of a witnessing pharmacy staff member for the purposes of receiving and stocking such narcotics for at least one year from the date the Registrant returns to work;
     
  6. The Registrant will not handle or physically prepare or dispense prescriptions for mood altering drugs (narcotics, opiates, opioids, benzodiazepines, and atypical sedatives such as zopiclone, zaleplon, and zolpidem and prescription psychostimulants such as dextroamphetamine, methylphenidate and modafinil), except if from time to time this is not possible, then the Registrant can only hand them to the patient and provide patient counselling for at least one year from the date the Registrant returns to work;
     
  7. The Registrant will not dispose or deal with wastage or breakage of or otherwise handle any mood altering drugs (narcotics, opiates, opioids, benzodiazepines, and atypical sedatives such as zopiclone, zaleplon, and zolpidem and prescription psychostimulants such as dextroamphetamine, methylphenidate and modafinil) for at least one year from the date the Registrant returns to work;
     
  8. The Registrant will not dispense own medications;
     
  9. Prior to the commencement of employment at any pharmacy, the Registrant shall disclose to the pharmacy manager and/or employer the limits and conditions on the Registrant’s license pursuant to this Consent Agreement if the pharmacy dispenses mood altering drugs (narcotics, opiates, opioids, benzodiazepines, and atypical sedatives such as zopiclone, zaleplon, and zolpidem and prescription psychostimulants such as dextroamphetamine, methylphenidate and modafinil);
     
  10. The Registrant will ensure that any pharmacy manager and/or employer with whom the Registrant secures employment in a pharmacy that dispenses mood altering drugs (narcotics, opiates, opioids, benzodiazepines, and atypical sedatives such as zopiclone, zaleplon, and zolpidem and prescription psychostimulants such as dextroamphetamine, methylphenidate and modafinil), submits a written statement to the College declaring their awareness of the Registrant’s medical condition and the Agreement. This statement must be received within 48 hours of securing employment and/or within 48 hours of any change of pharmacy manager at the Registrant’s place of employment;
     
  11. The Registrant will inform the College in writing, via e-mail, of  places of employment as a pharmacist and report any changes to the location of employment within 48 hours of such change. A reportable change to the Registrant’s place of employment contemplates both commencement and termination of employment;
     
  12. The Registrant will be restricted from acting in the following roles in the Registrant’s practice:
    1. Be a manager of a pharmacy;
    2. Be a director of a corporation that owns a pharmacy; and
    3. Act as a preceptor of pharmacy students and/or international pharmacy graduates.

This Agreement will remain in place until such time as the Registrant’s physician states otherwise. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant. The Inquiry Committee is satisfied that the undertakings will protect the public.

September 24, 2018
(December 19, 2018 - Registration Reinstated) 

The Inquiry Committee, pursuant to section 32.2(4)(b)(ii) Of the Health Professions Act, has reached an agreement with the pharmacist registrant to voluntarily suspend registration as a pharmacist effective September 24, 2018.  The agreement remains in effect until further notice.  The Inquiry Committee considers the agreement necessary to protect the public.  The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

Date of Dispositions: 
Friday, February 18, 2022